This story originally appeared on Zacks

Intersect ENT (XENT) posted a quarterly loss of $ 0.48 per share compared to Zacks’ consensus estimate of a loss of $ 0.42. This compares to a loss of $ 0.34 per share a year ago. These figures are corrected for non-recurring items.

– Zack

This quarterly report represents a surprise earnings of -14.29%. A quarter ago, this absorbable nasal implant maker was expected to record a loss of $ 0.42 per share when it actually produced a loss of $ 0.49, generating a surprise of -16.67%.

Over the past four quarters, the company hasn’t been able to beat consensus EPS estimates.

Intersect ENT, which is owned by Zacks Medical – Instruments industry, reported revenue of $ 24.4 million for the quarter ended September 2021, missing Zacks’ consensus estimate by 17.66%. This compares to revenue a year ago of $ 22.72 million. The company has beaten consensus revenue estimates three times in the past four quarters.

The sustainability of the immediate stock price movement based on recently released numbers and future earnings expectations will primarily depend on management feedback on the profit call.

Intersect ENT shares are up about 18.6% year-to-date against the 22.8% gain in the S&P 500.

What’s next for Intersect ENT?

While Intersect ENT has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?

There are no easy answers to this key question, but a reliable metric that can help investors solve this problem is the company’s earnings outlook. This not only includes the current consensus earnings expectations for the coming quarter (s), but also how those expectations have changed in recent times.

Empirical research shows a strong correlation between short-term stock market movements and trends in earnings estimate revisions. Investors can follow these revisions on their own or rely on a proven scoring tool like Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Prior to this publication of the results, the trend in revised estimates for Intersect ENT was mixed. While the magnitude and direction of estimate revisions may change as a result of the company’s just-released earnings report, the current status translates to a Zacks (Hold) rank of 3 for the stock. Thus, stocks are expected to move in line with the market in the near future. You can see the full list of Zacks # 1 Rank (Strong Buy) stocks today here.

It will be interesting to see how the estimates for the next quarters and the current year evolve in the days to come. Current consensus estimate of EPS is $ 0.35 on $ 37.13 million of revenue for the upcoming quarter and $ -1.77 on $ 118.44 million of revenue for the current year .

Investors should be aware that the outlook for the sector can also have a significant impact on the performance of the stock. In terms of Zacks industry rankings, Medical – Instruments is currently in the top 41% of the 250+ Zacks industries. Our research shows that the top 50% of industries ranked by Zacks outperform the bottom 50% by a factor of more than 2 to 1.

5 actions in the process of doubling

Each was selected by a Zacks expert as the # 1 favorite stock to earn + 100% or more in 2021. Previous recommendations climbed + 143.0%, + 175.9%, + 498.3% and + 673.0%.

Most of the stock in this report is flying under Wall Street’s radar, which provides a great opportunity to get into the ground floor.

Today, discover these 5 potential circuits >>

Want the latest recommendations from Zacks Investment Research? Today you can download 7 best stocks for the next 30 days. Click to get this free report

Intersect ENT, Inc. (XENT): Free Stock Analysis Report

To read this article on, click here.

Leave a Reply

Your email address will not be published.